PMV Pharmaceuticals
PMVP
93 hedge funds and large institutions have $65.6M invested in PMV Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 31 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.37% less ownership
Funds ownership: 83.09% → 78.72% (-4.4%)
6% less funds holding
Funds holding: 99 → 93 (-6)
10% less capital invested
Capital invested by funds: $72.7M → $65.6M (-$7.11M)
16% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 31
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
90% less call options, than puts
Call options by funds: $2K | Put options by funds: $20K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$4.88M |
| 2 |
EAM
Exome Asset Management
New York
|
+$646K |
| 3 |
AC
Aldebaran Capital
Carmel,
Indiana
|
+$633K |
| 4 |
D.E. Shaw & Co
New York
|
+$539K |
| 5 |
RC
RBF Capital
San Francisco,
California
|
+$457K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.51M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.85M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.16M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$964K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$857K |
PMVP Hedge Fund Activity: Q2 2024 in Review
93 of the 6,936 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q2 2024, worth a combined $65.6M — down 9.8% from $72.7M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of PMVP and 21 opened new positions — a net loss of 5 holders — while 31 trimmed existing stakes and 26 added.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $4.88M. The largest seller was BlackRock, cutting an estimated $3.51M.
- 93 institutional investors held PMV Pharmaceuticals (PMVP) as of Q2 2024, down from 99 in Q1 2024.
- Funds reported $65.6M of PMV Pharmaceuticals stock for Q2 2024, down 9.8% quarter-over-quarter.
- 21 funds opened new PMV Pharmaceuticals positions in Q2 2024 and 26 closed out, a net change of -5 holders.
- The largest PMV Pharmaceuticals buyer in Q2 2024 was Sio Capital Management, an estimated $4.88M added.
- The largest PMV Pharmaceuticals seller in Q2 2024 was BlackRock, an estimated $3.51M sold.
Based on aggregated 13F filings for Q2 2024.